{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"34"},{"groupId":"OG001","value":"9"},{"groupId":"OG002","value":"6"}]}],"title":"Hypertension"},{"categories":[{"measurements":[{"groupId":"OG000","value":"22"},{"groupId":"OG001","value":"4"},{"groupId":"OG002","value":"5"}]}],"title":"Hypotension"},{"categories":[{"measurements":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"0"}]}],"title":"Hypoxia"}],"denoms":[{"counts":[{"groupId":"OG000","value":"500"},{"groupId":"OG001","value":"134"},{"groupId":"OG002","value":"132"}],"units":"Participants"}],"description":"The number of participants who experienced adverse events related to vital sign measurements","groups":[{"description":"Induction Period (12 cycles): participants received lenalidomide 20 mg (10 mg if creatinine clearance ≥ 30 mL/min but \\< 60 mL/min) once daily on Days 1 to 21 of every 28-day Cycle for Cycles 1 to 12 AND rituximab 375 mg/m2 every week in Cycle 1 (Days 1, 8, 15, and 22) and Day 1 of every 28-day Cycle for Cycles 3, 5, 7, 9, and 11","id":"OG000","title":"Induction Period: Lenalidomide + Rituximab"},{"description":"Maintenance Period (18 Cycles): lenalidomide 10 mg once daily on Days 1 to 21 of every 28-day Cycle for Cycles 13 to 30 AND rituximab 375 mg/m2 on Day 1 of every 28-day Cycle for Cycles 13, 15, 17, 19, 21, 23, 25, 27, and 29. Followed by Optional Maintenance Period (up to PD): Lenalidomide 10 mg once daily on Days 1 to 21 of every 28-day Cycle up to PD. This treatment will be at the discretion of the participant and the investigator.","id":"OG001","title":"Arm A: Lenalidomide + Rituximab"},{"description":"Maintenance Period (18 Cycles): participants received rituximab 375 mg/m2 on Day 1 of every 28-day Cycle for Cycles 13, 15, 17, 19, 21, 23, 25, 27, and 29","id":"OG002","title":"Arm B: Rituximab"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"All treated participants","reportingStatus":"POSTED","timeFrame":"From first dose up to 30 days after last dose (up to approximately 64 weeks for induction period and 427 weeks for maintenance period)","title":"Participants Experiencing Adverse Events Related to Vital Signs","type":"SECONDARY","unitOfMeasure":"Participants"}